Royal Bank of Canada Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,252.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target decreased by Royal Bank of Canada from $1,282.00 to $1,252.00 in a report published on Tuesday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on REGN. Canaccord Genuity Group restated a buy rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Argus raised their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a research note on Tuesday, June 25th. JPMorgan Chase & Co. boosted their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an overweight rating in a research note on Friday, August 2nd. Truist Financial reissued a buy rating and issued a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday. Finally, Wells Fargo & Company reiterated an overweight rating and issued a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and an average price target of $1,118.62.

Regeneron Pharmaceuticals Trading Up 0.3 %

NASDAQ:REGN opened at $1,042.69 on Tuesday. Regeneron Pharmaceuticals has a 1 year low of $769.19 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The stock has a market cap of $114.89 billion, a price-to-earnings ratio of 31.20, a PEG ratio of 3.72 and a beta of 0.12. The business has a fifty day moving average of $1,129.33 and a 200-day moving average of $1,034.03.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.79 EPS. Equities analysts predict that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the sale, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,270 shares of company stock valued at $10,695,833. 7.48% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in REGN. Global Assets Advisory LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $339,594,000. Capital International Investors lifted its position in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after acquiring an additional 213,038 shares during the period. First Trust Advisors LP increased its holdings in Regeneron Pharmaceuticals by 115.2% in the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after buying an additional 195,902 shares during the period. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares in the last quarter. Finally, TD Asset Management Inc grew its position in Regeneron Pharmaceuticals by 162.9% in the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after acquiring an additional 166,998 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.